Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

GNLX

+ Watchlist+ Portfolio

Genelux Corp.

Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$2.00
52-Week Range
$1.77 – $5.89
Market Cap
$107.66M
P/E (TTM)
—
EPS (TTM)
-0.88
Dividend Yield
0.00%
Advanced Metrics
Price/Book
11.09
PEG Ratio
—
Return on Equity
-273.20%
Return on Assets
-105.89%
Gross Margin
100.00%
Operating Margin
-482825.00%
Profit Margin
0.00%
Current Ratio
1.16
Debt/Equity
0.26
Total Debt
$2.34M
Free Cash Flow
$-17.27M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$99.56M

Market Snapshot

About

Genelux Corp. is a clinical-stage biopharmaceutical company developing next-generation oncolytic viral immunotherapies for difficult-to-treat solid tumors. The company's lead product candidate Olvi-Vec is an attenuated vaccinia virus designed to selectively infect and destroy cancer cells while stimulating an anti-tumor immune response. Genelux is advancing multiple clinical programs evaluating Olvi-Vec as monotherapy and in combination with other cancer treatments for various tumor types. The company employs proprietary platform technology to engineer viruses with tumor-selective replication capabilities.